AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/27/19

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market (“ATM”) offerings of common shares in ...

The USPTO has issued  a notice of allowance to Aurinia Pharmaceuticals (NASDAQ: AUPH ) for patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, ...

Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 ...

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8 th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET. The presentation wi...

Read more ...

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Leidos Holdings, Inc. (NYSE:LDOS), Nomad Foods Limited (NYSE:NOMD), Hu...